70
Participants
Start Date
August 15, 2022
Primary Completion Date
February 28, 2026
Study Completion Date
June 30, 2026
Ivaltinostat
Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
Capecitabine
Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
RECRUITING
Clinical Research Alliance, Westbury
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
Penn State Hershey Cancer Institute, Hershey
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
University Cancer and Blood Center, Athens
RECRUITING
Norton Cancer Institute Audubon, Louisville
RECRUITING
Community Health Network, Indianapolis
RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
RECRUITING
University Medical Center New Orleans, New Orleans
RECRUITING
The University of Texas Southwestern Medical Center, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Utah Cancer Specialists, Salt Lake City
RECRUITING
HonorHealth Research Institute, Scottsdale
RECRUITING
UCLA Hematology/Oncology, Gastrointestinal Oncology, Santa Monica
RECRUITING
Hoag Medical Group, Newport Beach
RECRUITING
UCSF Medical Center, San Francisco
Lead Sponsor
CG Pharmaceuticals, Inc
INDUSTRY